# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Georgia O'Keeffe (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET011-SYN
- Date: 2026-03-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Wendell Ashby, MD
- Calendar frame: modern shifted

## What we are working on

- Afraid of losing the central vision she needs to paint **S**
- Wants to keep living alone and driving to her studio **S**

## Your goals

- Gain at least 10 ETDRS letters in the left eye by the end of the loading phase. Target: 2026-05-07. Recorded outcome: Left eye improved from 55 to 69 letters after three injections. **S**
- Dry macula on OCT (central subfield thickness below 300 um, no fluid) by the end of the loading phase. Target: 2026-05-07. Recorded outcome: Central subfield thickness fell from 418 to 274 um with no fluid. **S**
- Check the Amsler grid daily for each eye and report any change the same day. Target: 2026-07-02. Recorded outcome: Daily checks recorded; no new change in the right eye. **S**
- Complete a low-vision rehabilitation evaluation and set up studio lighting and magnification by the July visit. Target: 2026-07-02. Recorded outcome: Task lighting, a stand magnifier, and high-contrast labels in place; still painting daily. **S**

## What we agreed to do

- Same-week ophthalmology consultation for new distortion and reduced acuity in the left eye, with OCT and fluorescein or OCT angiography as needed. Guideline: Age-Related Macular Degeneration Preferred Practice Pattern (2024) **S**
- Intravitreal aflibercept 2 mg in the left eye every four weeks for three doses, then treat-and-extend by two-week steps while the macula stays dry. Guideline: Age-Related Macular Degeneration Preferred Practice Pattern (2024) **S**
- At each injection visit: best-corrected acuity, OCT, and intraocular pressure before and after injection; teach warning signs of endophthalmitis and retinal detachment. Guideline: Age-Related Macular Degeneration Preferred Practice Pattern (2024); CMID: Clinical Monitoring Intelligence Database, cataract and glaucoma monographs (eye-examination items) (2026) **S**
- Start an AREDS2 supplement (vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg, copper 2 mg daily) for intermediate AMD in the right eye; no beta-carotene. Guideline: Age-Related Macular Degeneration Preferred Practice Pattern (2024) **S**
- Daily home Amsler grid checks for each eye, with same-day calls for new distortion; dilated examination of the right eye at each retina visit. Guideline: Age-Related Macular Degeneration Preferred Practice Pattern (2024) **S**
- Low-vision rehabilitation: task lighting, magnification, high-contrast marking, home fall-risk review, and a driving assessment. Guideline: Age-Related Macular Degeneration Preferred Practice Pattern (2024); CMID: Clinical Monitoring Intelligence Database, cataract and glaucoma monographs (eye-examination items) (2026) **S**
- Repeat the PHQ-2 at follow-up because vision loss raises the risk of depression. Guideline: CMID: Clinical Monitoring Intelligence Database, cataract and glaucoma monographs (eye-examination items) (2026) **S**

## Follow-up

- 2026-03-10: Primary care visit for new wavy lines and a blurred spot in the left eye **S**
- 2026-03-12: Ophthalmology consultation, retinal imaging, and first anti-VEGF injection **S**
- 2026-04-09: Four-week retina follow-up with OCT and second injection **S**
- 2026-05-07: Eight-week retina follow-up with OCT and third injection **S**
- 2026-07-02: Treat-and-extend retina visit and primary care review of vision rehabilitation **S**
- 2026-10-15: Subsequent annual wellness visit **S**

This teaching document does not replace care from a qualified clinician.
